Crossmark

The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease

Crossref DOI link: https://doi.org/10.1016/j.kint.2019.12.007

Published Print: 2020-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Hasegawa, Sho https://orcid.org/0000-0002-0798-9400
Tanaka, Tetsuhiro

Saito, Tomoyuki

Fukui, Kenji

Wakashima, Takeshi

Susaki, Etsuo A.

Ueda, Hiroki R.

Nangaku, Masaomi https://orcid.org/0000-0001-7401-2934
Funding

Funding for this research was provided by:

University of Tokyo

Japan Society for the Promotion of Science (17K09688)

Japan Society for the Promotion of Science (18H02824)

Japan Society for the Promotion of Science (19J11928)

Japan Society for the Promotion of Science (26111003)
License Information

Text and Data Mining valid from 2020-05-01

Text and Data Mining valid from 2020-05-01

Version of Record valid from 2020-01-03
More Information

This article is maintained by: Elsevier

Article Title: The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease

Journal Title: Kidney International

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.kint.2019.12.007

Content Type: article

Copyright: © 2020 International Society of Nephrology. Published by Elsevier Inc.

Document is current

Any future updates will be listed below